Betalactam antibiotics;Antibióticos betalactámicos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 1, 2003, Pages 42-55

  Marín, Mar ^a   Gudiol, Francesc ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Antimicrobial agents; Betalactams; Clinical use

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZLOCILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFALOTIN; CEFAMANDOLE; CEFAZOLIN; CEFONICID; CEFORANIDE; CEFOTETAN; CEFOXITIN; CEFRADINE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; METICILLIN; MEZLOCILLIN; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; UNINDEXED DRUG; UREIDOPENICILLIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; BACTERIAL CELL WALL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BLEEDING; BRAIN DISEASE; COLITIS; COMMUNICABLE DISEASE; CONFUSION; CONVULSION; DERMATITIS; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EOSINOPHILIA; FEVER; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HEMOLYTIC ANEMIA; HEPATITIS; HOSPITAL INFECTION; HUMAN; INTERSTITIAL NEPHRITIS; LARYNX EDEMA; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MULTIDRUG RESISTANCE; MYOCLONUS; MYOSITIS; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PHLEBITIS; PROPHYLAXIS; PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN INDURATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SURGICAL INFECTION; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREMOR; URTICARIA; VAGINA CANDIDIASIS; VAGINITIS; VOMITING;

EID: 0037263722     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042137     Document Type: Review

References (43)

1. Abraham EP, Chain E, Fletcher CM, et al. Further observations on penicillin. Lancet 1941;2:177-89.
2. Cantón R. Lectura interpretada del antibiograma: ¿ejercicio intelectual o necesidad clínica? Enferm Infecc Microbiol Clin 2002;20:176-86.
3. Navarro F, Miró E, Mirelis B. Lectura interpretada del antibiograma de enterobacterias. Enferm Infecc Microbiol Clin 2002;20:225-34.
4. Torres C. Lectura interpretada del antibiograma de cocos grampositivos. Enferm Infecc Microbiol Clin 2002;20:354-64.
5. Drusano GL. Role of pharmacokinetics in the outcome of infeccions. Antimicrob Agents Chemother 1988;32:289-97.
6. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
7. Spivey JM. The postanbiotic effect. Clin Pharm 1992;11:865-75.
8. Davis BD. Bactericidal synergism between beta-lactams and aminoglycosides: Mechanisms and possible therapeutic implications. Rev Infect Dis 1982;4:237-45.
9. Poole K. Multidrug resistance in gram-negative bacteria. Curr Opin Microbiol 2001;4:500-8.
10. Smith AM, Klugman KP, Coffey TJ, Spratt BG. Genetic diversity of penicillin-binding protein 2B and 2X genes from Streptococcus pneumoniae in South Africa. Antimicrob Agents Chemother 1993;37:1938-44.
11. De Lencastre H, Sa Figueiredo AM, Urban C, Rahal J, Tomasz A. Multiple mechanisms of methicillin resistance and improved methods for detection in clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 1991;35:632-9.
12. Bush K, Jacoby GA, Medeiros AA. A functional classifications scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
13. Pérez-Trallero E, Fernández-Mazarrasa C, García-Rey C, Bouza E, Aguilar L, García de Lomas J, et al. Antimicrobial susceptibility of 1684 Streptococcus pneumoniae and 2039 Streptococcus pyogenes isolates and their ecological relationship. Results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001;45:3334-40.
14. Liñares J, Tubau F, Dominguez MA. Antibiotic resistance in Streptococcus pneumoniae in Spain: An overview of the 1990s. En: Tomasz A, editor. Streptococcus pneumoniae: Molecular biology and mechanisms of disease. New York: Mary Ann Liebert, 1999; p. 399-409.
15. Liñares J, Alonso T, Pérez JL, Ayats J, Domínguez MA, Pallarés R, et al. Decreased susceptibility of penicillin-resistant penumococci to twenty-four β-lactam antibiotics. J Antimicrob Chemother 1992;30:279-88.
16. Cercenado E, García-Leoni ME, Rodeño P, Rodríguez-Creixems M. Ampicillin-resistant enterococci. Antimicrob Agents Chemother 1990;28:829.
17. Schwarez SK, Zenilamn JM, Schenell D, Knapp JS, Hook EW, Thompson S, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. JAMA 1990;264:1413-7.
18. Prats G, Mirelis B, Llovet T, Muñoz C, Miro E, Navarro F. Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985-1987 and 1995-1998 in Barcelona. Antimicrobial Agents and Chemotherapy 2000;44:1140-5.
19. st century: Characterisation, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.
20. Sanders WE Jr, Tenney JM, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996;23:454-61.
21. a ed. Barcelona: Masson, 2002.
22. Ariza J, Sánchez C, Gomis M, Barberán J, Barros C. Infecciones osteoarticulares y de partes blandas. En: Aguado JM, Almirante B, Fortún J, editors. Protocolos Clínicos SEIMC 2002;6:3-26.
23. Rodrigo C, Del Castillo F, García Martín F, Moreno D, Ruiz Contreras J. Infecciones de las vías respiratorias superiores. En: Aguado JM, Almirante B, Fortún J, editors. Protocolos Clínicos SEIMC 2002;3:3-30.
24. Falguera M, Gudiol F, Sabriá M, Alvarez-Lerma E, Cordero E. Infecciones en el tracto respiratorio inferior. En: Aguado JM, Almirante B, Fortún J, editors. Protocolos Clínicos SEIMC 2002;3:3-42.
25. Roson B, Carratalá J, Tubau F, Dorca J, Liñares J, Pallarés R, et al. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: A randomized study of amoxicillin-clavulanate and ceftriaxone. Microbiol Drug Resistance 2001;7:85-96.
26. Francioli P, Chastre J, Langer M, Santos JI, Shah PM, Torres A. Ventilator-associated pneumonia: Understanding epidemiology and pathogenesis to guide prevention and empiric therapy. Clin Microbiol Infect 1997;3(Suppl 1):S61-S76.
27. Fernández Guerrero M, Alarcón A, Fortún J, Llinares P. Endocarditis e infecciones cardiovasculares. En: Aguado JM, Almirante B, Fortún J, editors. Protocolos Clínicos SEIMC 2002;5:3-31.
28. Wilson WR, Karchmer AW, Dajani AS, Taubert KA, Bayer A, Kaye D, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci and HACEK microorganisms. JAMA 1995;274:1706-13.
29. Gavalda J, Torres C, Tenorio C, López P, Zaragoza M, Capdevila JA, et al. Efficacy of ampicillin plus ceftriaxona in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother 1999;43:639-46.
30. Cabellos C, Navas E, Martínez-Lacasa J, Gatell JM. Infecciones del sistema nervioso central. En: Aguado JM, Almirante B, Fortún J, editors. Protocolos Clínicos SEIMC 2002;2:3-26.
31. Cabellos C, Fernández-Viladrich P, Verdaguer R, Pallarés R, Liñares J, Gudiol F. A single daily dose of ceftriaxone for bacterial meningitis in adults: Experience with 84 patients and review of the literature. Clin Infect Dis 1995;20:1164-8.
32. Viladrich PF, Cabellos C, Pallarés R, Tubau F, Martínez-Lacasa J, Liñares J, et al. High doses of cefotaxime in treatment of adult meningitis due to streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1196;40:218-20.
33. Gurgui M, Moreno A, Sitges-Serra A, Blanes M. Peritonitis y otras infecciones intraabdominales. En: Aguado JM, Almirante B, Fortún J, editors. Protocolos Clínicos SEIMC 2002;9:3-40.
34. Ariza J, Xiol J, Esteve M, Fernández-Bañeres F, Liñares J, Alonso T, et al. Aztreonam versus cefotaxime in the treatment of Gram-negative spontaneous peritonitis in cirrhotic patients. Hepatology 1991;14:91-8.
35. Pigrau C, Horcajada JC, Cartón JA, Pujol M. Infección urinaria. En: Aguado JM, Almirante B, Fortún J, editors. Protocolos Clínicos SEIMC 2002;4:3-30.
36. Gudiol F, Pallarés R, Ariza J, Viladrich PF, Rufi G, Liñares J. Comparative clinical evaluation of aztreonam versus aminoglycosides in Gram-negative septicemia. J Antimicrob Chemother 1986;17:661-71.
37. Pujol M, Gudiol F. Evidenee of antibiotic cycling in control of resistance. Curr Opin Infect Dis 2001;14:711-5.
38. Berenguer J, Lizasoaín M, Carratalá J, Capdevila JA. Infecciones en el paciente neutropénico. En: Aguado JM, Almirante B, Fortún J, editors. Protocolos Clínicos SEIMC 2002;11:5-33.
39. González-Barca E, Fernández-Sevilla A, Carratalá J, Grañena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996;15:291-6.
40. Carratalá J, Alcaide F, Fernández-Sevilla A, Corbella X, Liñares J, Gudiol F. Bacteremia due to viridans streptococi that are highly resistant to penicillin: Increase among neutropenic patients with cancer. Clin Infect Dis 1995;20:1169-73.
41. Alcaide F, Liñares J, Pallarés R, Benítez MA, Gudiol F, Martín R. In vitro actrivities of 22 β-lactam antibiotics against penicillin resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 1995;39:2243-7.
42. Lin RY. A perspective on penicillin allergy. Arch Intern Med 1992;15:930-7.
43. Pallarés R, Pujol M, Peña C, Ariza J, Gudiol F, Martín R. Cephalosporins as a risk factor for Nosocomial Enterococcus faecalis bacteremia: A matched case-control study. Arch Intern Med 1993;153:1581-6.